Tanabe Mitsubishi Pharma revised its medium-term management plan downward and plans to consolidate its domestic research centers and plants while strengthening its development organization in the United States, President Masayuki Mitsuya (三津家 正之) said. The company aims to commercialize digital medicine by 2025, and he also expressed the view that the number of managers could be reduced to approximately one-fifth of the current level.
In November 2018, Tanabe Mitsubishi Pharma revised downward the management targets set out in its medium-term management plan in response to changes in the business environment. It indicated a policy of consolidating its domestic research centers and plants to reduce costs while strengthening its development organization in the United States.
President Masayuki Mitsuya (三津家 正之) was described as expressing his determination to fundamentally change the company's internal structure, despite his calm manner of speaking. The article describes specific workforce reductions and organizational restructuring, but these are not used here as facts; the explanation centers on the change in policy.
The article gives a target of 2025 for the commercialization of digital medicine and also discusses the streamlining of the management structure.
Overall, the article depicts a two-part strategic shift involving the consolidation and integration of domestic sites and stronger development activities in the United States, with follow-up reports on the execution plan and progress expected to attract attention.